Table 1.
Clinical Features of the UC Cases and Controls
| Feature | UC | Controls | P value |
|---|---|---|---|
| N=72* | N=90* | ||
| Mean age (Range) | 52 (21–78) | 59 (29–79) | 0.0004 |
| Race (white) | 69 (96%) | 75 (83%) | 0.01 |
| M/F ratio | 1.3:1 | 1:0.8 | 0.15 |
| Smoking | 9 (12%) | 9 (11%) | 0.81 |
| Alcohol | 50 (69%) | 59 (74%) | 0.56 |
| NSAIDs | 6 (8%) | 15 (17%) | 0.12 |
| Bowel Prep | <0.001 | ||
| - Go-Lytely | 9 (13%) | 16 (18%) | |
| - Half-Lytely | 23 (32%) | 21 (23%) | |
| - Miralax | 12 (17%) | 42 (47%) | |
| - Fleet phosphosoda | 10 (14%) | 0 (0%) | |
| - Magnesium citrate | 16 (22%) | 8 (8.9%) | |
| - Other | 2 (2.8%) | 3 (3.3%) | |
| Medication | |||
| - Oral mesalamine | 46 (64%) | n/a | |
| - Azathioprine/6-MP | 16 (22%) | n/a | |
| - Infliximab | 2 (3%) | n/a | |
| - Corticosteroid | 3 (4%) | n/a | |
| - Antibiotic/Probiotic | 7 (10%) | n/a | |
| Mean duration of disease (years) | 9.9 (1–38) | n/a | |
| Prior known extent of disease | |||
| -Proctitis | 4 (6%) | n/a | |
| -Left-sided | 24 (33%) | n/a | |
| -Subtotal | 30 (42%) | n/a | |
| -Total | 12 (17%) | n/a | |
| -Unknown | 2 (3%) | n/a | |
| Extraintestinal Manifestations (ever) |
|||
| - Primary sclerosing cholangitis |
1 (1%) | n/a | |
| - Arthritis | 8 (11%) | n/a | |
| - Iritis | 2 (3%) | n/a | |
| - Pyoderma gangrenosum | 2 (3%) | n/a | |
| - Erythema nodosum | 2 (3%) | n/a |
*
The denominators vary due to missing values
n/a: not applicable